Smallpox Vaccine Scar: Who Has One and Why?
Global Pneumococcal Vaccines Market To Witness Steady Growth, Projected To Surpass US$ 13.3 Billion By 2033
Pneumococcal Vaccines Market The global pneumococcal vaccines market is poised to exhibit steady growth, with an anticipated Compound Annual Growth Rate (CAGR) of 4.1% during the forecast period. According to the latest insights from Future Market Insights, the market's valuation reached US$ 8.9 Billion in 2023, and it is expected to surpass US$ 13.3 Billion by 2033.
Analysts at Future Market Insights have recorded a historical market valuation of US$ 8.5 Billion for the pneumococcal vaccines market during the base year, underlining the sector's sustained growth trajectory.
Request For A Sample: https://www.Futuremarketinsights.Com/reports/sample/rep-gb-7078
Pneumococcal vaccines play a crucial role in preventing diseases caused by Streptococcus pneumoniae bacteria, including pneumonia, meningitis, and bloodstream infections. With increasing awareness about the importance of vaccination and rising initiatives by healthcare organizations worldwide, the demand for pneumococcal vaccines is anticipated to witness significant growth over the forecast period.
Key factors contributing to the market's growth include advancements in vaccine development technologies, expanding immunization programs, and rising investments in healthcare infrastructure. Additionally, the growing prevalence of pneumococcal infections, particularly among children and the elderly, underscores the urgent need for effective vaccination strategies.
The projected growth of the pneumococcal vaccines market signifies opportunities for stakeholders, including vaccine manufacturers, healthcare providers, and policymakers, to collaborate and address the global burden of pneumococcal diseases.
The factors supporting the growth of the pneumococcal vaccines industry is spot on. Here's a breakdown of why each element contributes:
Overall, these factors create a positive outlook for the pneumococcal vaccines industry, with a projected growth in the coming years.
Customization Available Request: https://www.Futuremarketinsights.Com/customization-available/rep-gb-7078
Key Takeaways from the Pneumococcal Vaccines Market:
Competitive Landscape:
Leading Industry Players Illuminate Opportunities Amidst Technological Advancements The pneumococcal vaccines market thrives in its diversity, as major manufacturers employ a variety of strategies to stay ahead of the competition. Through both organic growth and strategic acquisitions, industry giants are investing heavily in research and development to enhance the efficacy of pneumococcal vaccines, particularly in addressing chronic illnesses prevalent among aging populations.
Activirosomes, for instance, pioneers the development of viral infection vaccines. Harnessing active virosome technology, the company engineers non-replicating derivatives of measles and other viruses, focusing solely on essential viral genes that trigger robust immune responses.
Recent Developments:
Some of the key players proliferating in the market are:
Request Purchase Now: https://www.Futuremarketinsights.Com/checkout/7078
Key Segments in the Pneumococcal Vaccines Market:
By Product Type:
By Distribution Channel:
By Region:
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube
Pneumococcal Vaccine Schedule: High Risk Pediatrics
With Chronic Medical Conditions Chronic heart disease3 PCV15 or PCV202 doses ≥8wks apartMissing 4th dose only:PCV15 or PCV201 dose to complete series
Previously received PCV20:No additional vaccine6
PCV20 included in the series:No additional vaccine6Only PCV13 or PCV15 used in the series:PCV20 or PPSV2371 dose ≥8wks after last PCV dose12
No additional vaccine6 PCV15 or PCV201 dose ≥8wks after last pneumococcal vaccine8If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not previously given PCV20 or PPSV231 dose ≥8wks after last PCV dose12 No additional vaccine6 Chronic kidney disease4 Chronic liver disease Chronic lung disease5 Diabetes mellitus Cerebrospinal fluid leak Cochlear implant With Immunocompromising Conditions Maintenance dialysis or with nephrotic syndrome PCV15 or PCV202 doses ≥8wks apartMissing 4th dose only:PCV15 or PCV201 dose to complete series
Previously received PCV20:No additional vaccine6
PCV20 included in the series:No additional vaccine6Only PCV13 or PCV15 used in the series: PCV2010 or PPSV2371 dose ≥8wks after last PCV dose. If PPSV23 used, revaccinate with 1 dose PCV20 or PPSV23 ≥5yrs after the first PPSV23 dose12
No additional vaccine at this timeRevaccinate with 1 dose PCV20 or PPSV23 ≥5yrs after the first PPSV23 dose12 PCV15 or PCV201 dose ≥8wks after last pneumococcal vaccine8If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not previously given PCV2010or PPSV2371 dose ≥8wks after last PCV dose. If PPSV23 used, revaccinate with 1 dose PCV20 or PPSV23 ≥5yrs after the first PPSV23 dose12 No additional vaccine at this timeRevaccinate with 1 dose PCV20 or PPSV23 ≥5yrs after the first PPSV23 dose12 Congenital or acquired asplenia or splenic dysfunction Congenital or acquired immunodeficiencies9 Conditions treated with immunosuppressants or radiation therapy11 HIV infection Sickle cell disease or other hemoglobinopathies NOTESKey: PCV = pneumococcal conjugate vaccine; PCV15 = 15-valent PCV; PCV20 = 20-valent PCV; PPSV23 = 23-valent pneumococcal polysaccharide vaccine
1 Any incomplete PCV schedule with <3 doses before age 2yrs.
2 Completed all recommended PCV doses before age 6yrs.
3 Especially in children with cyanotic congenital heart disease and cardiac failure.
4 Excludes maintenance dialysis and nephrotic syndrome.
5 Includes moderate persistent or severe persistent asthma.
6 Pneumococcal vaccines are complete.
7 Recommended for children aged ≥2yrs with no previous PCV20 vaccination.
8 Give dose regardless of whether the child has previously received PPSV23 or PCV7.
9 Includes B-(humoral) or T-lymphocyte deficiency, complement deficiencies particularly C1/C2/C3/C4 deficiency, phagocytic disorders (excluding chronic granulomatous disease).
10 If PCV20 is used, their vaccines are then complete.
11 Includes malignant neoplasms, leukemias, lymphomas, Hodgkin disease, solid organ transplant.
12 Regardless of vaccine used, their vaccines are then complete.
REFERENCECenters for Disease Control and Prevention. ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:1072. DOI: http://dx.Doi.Org/10.15585/mmwr.Mm7239a5
Centers for Disease Control and Prevention. Pneumococcal Vaccination: Summary of Who and When to Vaccinate. Https://www.Cdc.Gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.Html#children-6-18. Accessed March 19, 2024.
Created 3/2024
Let's Give It A Shot: Free Vaccines Available At Local Health Centers
MANILA, Philippines – This World Immunization Week, the World Health Organization marks 50 years since it launched the Expanded Program on Immunization (EPI) to ensure vaccine accessibility and availability to all children.
With the rise in whooping cough and measles cases across the country, the Department of Health (DOH) encourages the public to participate in its immunization campaign against vaccine-preventable diseases, reminding them to get a variety of free vaccines from their local health centers.
In the Philippines, the Expanded Program on Immunization was established in 1976 to ensure that infants, children, and mothers have access to age-recommended vaccines.
According to Republic Act No. 10152 or the "Mandatory Infants and Children Health Immunization Act of 2011", mandatory basic immunization is to be given for free at any government hospital or health center to infants and children up to five years of age.
Here is a list of the different vaccines available for free in the Philippines.
BCG vaccineThe World Health Organization (WHO) recommends that the Bacille Calmette-Guérin vaccine be given to infants at birth for protection against tuberculosis (TB), an infection that most often affects the lungs.
It also protects them against meningitis and disseminated TB in children, as the disease can affect other parts of the body like the brain, bones, joints, and other internal organs.
Hepatitis-B vaccineThe Hepatitis-B vaccine should be given at birth for prevention against the virus, which can develop into long-term infections in the liver, such as liver damage and liver cancer.
Pentavalent vaccineThe Pentavalent vaccine is a 5-in-1 vaccine that protects children against these five diseases: Diphtheria, Pertussis, Tetanus, Hepatitis B, and Haemophilus influenza type B. This vaccine is given in three doses, from 6, 10, and 14 weeks of age.
Pertussis or whooping cough causes coughing spells, which can easily spread among people through coughs and sneezes because of airborne droplets. With recent reports of pertussis outbreaks across cities and provinces in the Philippines, immunization through the Pentavalent vaccine is pertinent.
PCV vaccineThe PCV or Pneumococcal Conjugate vaccine prevents pneumococcal diseases which are infections caused by a bacteria called Streptococcus pneumoniae, or pneumococcus. Examples of such diseases are pneumonia and meningitis, which are common causes of sickness and death among children below 2 years old. This vaccine is also given in three doses, at a recommendation of 6, 10, and 14 weeks of age.
Oral Polio vaccine and Inactivated Polio vaccine (Poliovirus)The two vaccines serve as protection against the poliovirus, a disease that causes permanent paralysis or loss of mobility in the limbs and, in severe cases, the paralysis of the breathing muscles which can lead to death. The oral polio vaccine is given in three doses, recommended at 6, 10, and 14 weeks of age while the inactivated polio vaccine is given at 14 weeks.
MMR vaccineThe MMR vaccine is a preventive vaccine against measles, mumps, and rubella and the complications that come with these diseases. It must be given in two doses: at nine months and one year old.
Measles is a highly contagious disease with symptoms that include high fever, runny nose, cough, red and watery eyes, and rashes. After the Bangsamoro Autonomous Region in Muslim Mindanao health ministry declared a measles outbreak within the region, a free measles vaccination campaign was launched in the region.
Aside from children, the government also provides immunization healthcare to its senior population. In 2020, the DOH issued Memorandum No. 2020-0384, announcing the senior citizens' free access to pneumococcal and influenza immunization services.
The memorandum also states that all senior citizens who are 60 years old and above are provided with one dose of pneumococcal vaccine throughout their lifetime and one dose of influenza vaccine every year. All eligible senior citizens are to be assessed and interviewed before immunization for precautions. – Isabella Baldado/Rappler.Com
SOURCES:
Isabella Baldado is a Digital Communications volunteer at Rappler and a speech communication student at the University of the Philippines Diliman. This article was done under the supervision of Rappler staff and her copy was vetted by editors.
Comments
Post a Comment